OpenLB
Open Library of Bioscience
Advanced Search
Cells
09 21, 2022;11 (19):

Single-Cell Gene Expression Analysis Revealed Immune Cell Signatures of Delta COVID-19.

Abusaid M Shaymardanov, Olga A Antonova, Anastasia D Sokol, Kseniia A Deinichenko, Polina G Kazakova, Mikhail M Milovanov, Alexander V Zakubansky, Alexandra I Akinshina, Anastasia V Tsypkina, Svetlana V Romanova, Vladimir E Muhin, Sergey I Mitrofanov, Vladimir S Yudin, Sergey M Yudin, Antonida V Makhotenko, Anton A Keskinov, Sergey A Kraevoy, Ekaterina A Snigir, Dmitry V Svetlichnyy, Veronika I Skvortsova
Author Information
  1. Abusaid M Shaymardanov: Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia. ORCID
  2. Olga A Antonova: Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  3. Anastasia D Sokol: Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  4. Kseniia A Deinichenko: Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  5. Polina G Kazakova: Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia. ORCID
  6. Mikhail M Milovanov: Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  7. Alexander V Zakubansky: Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  8. Alexandra I Akinshina: Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  9. Anastasia V Tsypkina: Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  10. Svetlana V Romanova: Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  11. Vladimir E Muhin: Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia. ORCID
  12. Sergey I Mitrofanov: Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia. ORCID
  13. Vladimir S Yudin: Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia. ORCID
  14. Sergey M Yudin: Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  15. Antonida V Makhotenko: Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  16. Anton A Keskinov: Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  17. Sergey A Kraevoy: Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  18. Ekaterina A Snigir: Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia.
  19. Dmitry V Svetlichnyy: Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical-Biological Agency, 10 Bld., 1 Pogodinskaya Str., Moscow 119121, Russia. ORCID
  20. Veronika I Skvortsova: The Federal Medical Biological Agency (FMBA of Russia), 30 Volokolamskoe sh., Moscow 125310, Russia.
PMID: 36230912 DOI: 10.3390/cells11192950

Abstract

The coronavirus disease 2019 (COVID-19) is accompanied by a cytokine storm with the release of many proinflammatory factors and development of respiratory syndrome. Several SARS-CoV-2 lineages have been identified, and the Delta variant (B.1.617), linked with high mortality risk, has become dominant in many countries. Understanding the immune responses associated with COVID-19 lineages may therefore aid the development of therapeutic and diagnostic strategies. Multiple single-cell gene expression studies revealed innate and adaptive immunological factors and pathways correlated with COVID-19 severity. Additional investigations covering host-pathogen response characteristics for infection caused by different lineages are required. Here, we performed single-cell transcriptome profiling of blood mononuclear cells from the individuals with different severity of the COVID-19 and virus lineages to uncover variant specific molecular factors associated with immunity. We identified significant changes in lymphoid and myeloid cells. Our study highlights that an abundant population of monocytes with specific gene expression signatures accompanies Delta lineage of SARS-CoV-2 and contributes to COVID-19 pathogenesis inferring immune components for targeted therapy.

Keywords

COVID-19 immune system monocytes single-cell transcriptome

References

Nat Commun. 2021 Oct 7;12(1):5890 [PMID: 34620862]
Nat Rev Genet. 2011 Dec 06;13(1):59-69 [PMID: 22143240]
Sci Adv. 2020 Dec 9;6(50): [PMID: 33187979]
Immunity. 2020 Dec 15;53(6):1296-1314.e9 [PMID: 33296687]
Nat Commun. 2021 Feb 17;12(1):1088 [PMID: 33597522]
J Immunol. 2021 Oct 1;207(7):1848-1856 [PMID: 34452933]
Cell Rep. 2020 Jun 30;31(13):107826 [PMID: 32610127]
Nat Rev Genet. 2012 Jun 18;13(7):469-83 [PMID: 22705667]
Nat Commun. 2021 Aug 9;12(1):4888 [PMID: 34373466]
Nat Commun. 2021 Jul 5;12(1):4117 [PMID: 34226537]
Infect Genet Evol. 2020 Nov;85:104422 [PMID: 32544615]
Nat Cell Biol. 2021 Dec;23(12):1314-1328 [PMID: 34876692]
Proc Natl Acad Sci U S A. 2021 Aug 17;118(33): [PMID: 34385315]
Cell Rep. 2021 Jul 20;36(3):109414 [PMID: 34260965]
Nat Rev Microbiol. 2021 Jul;19(7):409-424 [PMID: 34075212]
Front Pharmacol. 2021 Jun 07;12:673485 [PMID: 34163359]
Proc Natl Acad Sci U S A. 2020 Sep 15;117(37):22932-22943 [PMID: 32859762]
Nat Med. 2021 May;27(5):904-916 [PMID: 33879890]
Cell Mol Gastroenterol Hepatol. 2015 Nov 1;1(6):646-663.e4 [PMID: 26783552]
PLoS One. 2020 Dec 31;15(12):e0241097 [PMID: 33382687]
OMICS. 2012 May;16(5):284-7 [PMID: 22455463]
Eur J Immunol. 2022 Jan;52(1):138-148 [PMID: 34676541]
Int Rev Cell Mol Biol. 2022;367:1-28 [PMID: 35461655]
Immunity. 2021 Nov 9;54(11):2650-2669.e14 [PMID: 34592166]
Immunity. 2021 Apr 13;54(4):797-814.e6 [PMID: 33765436]
Cell. 2019 Feb 7;176(4):775-789.e18 [PMID: 30595452]
J Immunol. 2021 Jun 15;206(12):2785-2790 [PMID: 34049971]
Sci Rep. 2013;3:1215 [PMID: 23386971]
Cell. 2020 Aug 20;182(4):812-827.e19 [PMID: 32697968]
Genes (Basel). 2021 Apr 24;12(5): [PMID: 33923155]
PLoS One. 2014 Nov 06;9(11):e112150 [PMID: 25375657]
Med (N Y). 2021 Jun 11;2(6):755-772.e5 [PMID: 33870241]
Cell. 2021 Jun 24;184(13):3573-3587.e29 [PMID: 34062119]
Cell. 2021 Apr 1;184(7):1895-1913.e19 [PMID: 33657410]
Nat Methods. 2019 Dec;16(12):1289-1296 [PMID: 31740819]
Nat Methods. 2017 Nov;14(11):1083-1086 [PMID: 28991892]
J Exp Med. 2006 May 15;203(5):1153-9 [PMID: 16682497]
Annu Rev Immunol. 2022 Apr 26;40:387-411 [PMID: 35119910]
Front Immunol. 2020 Nov 18;11:603507 [PMID: 33312178]
Front Immunol. 2021 Feb 24;12:625881 [PMID: 33717140]
Cell Rep. 2022 Jul 26;40(4):111148 [PMID: 35858624]
Expert Rev Clin Immunol. 2014 May;10(5):593-619 [PMID: 24678812]
Nat Rev Immunol. 2020 May;20(5):269-270 [PMID: 32273594]
Science. 2021 Feb 5;371(6529): [PMID: 33408181]
Immunol Lett. 2021 Jul;235:9-14 [PMID: 33901540]
Cell Rep. 2021 Oct 5;37(1):109793 [PMID: 34587478]
Nat Med. 2020 Jul;26(7):1070-1076 [PMID: 32514174]
BMC Bioinformatics. 2021 Jul 17;22(1):373 [PMID: 34273961]
Hum Immunol. 2021 Mar;82(3):170-176 [PMID: 33531264]
J Immunol. 2013 Apr 15;190(8):4349-59 [PMID: 23509368]
Cell Biol Int. 2022 Jul;46(7):1109-1127 [PMID: 35521908]
Cell. 2020 Sep 17;182(6):1419-1440.e23 [PMID: 32810438]
Exp Biol Med (Maywood). 2021 Mar;246(6):688-694 [PMID: 33302737]
Immunity. 2020 Oct 13;53(4):864-877.e5 [PMID: 32791036]
Lancet Infect Dis. 2020 Nov;20(11):1263-1272 [PMID: 32679081]
Int J Mol Sci. 2021 May 26;22(11): [PMID: 34073283]
Front Immunol. 2020 Nov 30;11:598404 [PMID: 33329592]
Nature. 2021 Dec;600(7888):295-301 [PMID: 34695836]
Immunity. 2021 Aug 10;54(8):1883-1900.e5 [PMID: 34331874]
Nat Cell Biol. 2021 May;23(5):538-551 [PMID: 33972731]
J Immunol. 2022 Jan 15;208(2):396-406 [PMID: 34911770]
Front Immunol. 2021 Jul 28;12:716407 [PMID: 34394121]
Science. 2020 Aug 7;369(6504):718-724 [PMID: 32661059]
Front Immunol. 2020 Dec 03;11:611004 [PMID: 33343585]

MeSH Term

COVID-19
Gene Expression
Humans
Immunologic Factors
SARS-CoV-2

Chemicals

Immunologic Factors
Journal Article Research Support, Non-U.S. Gov't

Word Cloud

Similar Articles

Cited By